COPENHAGEN, Denmark--(BUSINESS WIRE)--Santaris Pharma announced today that SPC3042, a RNA-based antisense oligonucleotide developed using the company’s proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol®) in both model systems. The data on SPC3042 was published in the September 2008 issue of the journal Molecular Cancer Therapeutics.
